Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist

Vivek Subbiah, Robert E. Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1-5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease.

Original languageEnglish
Pages (from-to)2541-2546
Number of pages6
JournalMolecular Cancer Therapeutics
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

TNF-Related Apoptosis-Inducing Ligand Receptors
Chondrosarcoma
Death Domain Receptors
Lung Diseases
human TNFSF10 protein
Up-Regulation
Therapeutics
Immunohistochemistry
Tomography
Apoptosis
Ligands
Lung
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. / Subbiah, Vivek; Brown, Robert E.; Buryanek, Jamie; Trent, Jonathan; Ashkenazi, Avi; Herbst, Roy; Kurzrock, Razelle.

In: Molecular Cancer Therapeutics, Vol. 11, No. 11, 01.11.2012, p. 2541-2546.

Research output: Contribution to journalArticle

Subbiah, Vivek ; Brown, Robert E. ; Buryanek, Jamie ; Trent, Jonathan ; Ashkenazi, Avi ; Herbst, Roy ; Kurzrock, Razelle. / Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. In: Molecular Cancer Therapeutics. 2012 ; Vol. 11, No. 11. pp. 2541-2546.
@article{6b9b513f42964dd2829958fda4be3e04,
title = "Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist",
abstract = "Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1-5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease.",
author = "Vivek Subbiah and Brown, {Robert E.} and Jamie Buryanek and Jonathan Trent and Avi Ashkenazi and Roy Herbst and Razelle Kurzrock",
year = "2012",
month = "11",
day = "1",
doi = "10.1158/1535-7163.MCT-12-0358",
language = "English",
volume = "11",
pages = "2541--2546",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist

AU - Subbiah, Vivek

AU - Brown, Robert E.

AU - Buryanek, Jamie

AU - Trent, Jonathan

AU - Ashkenazi, Avi

AU - Herbst, Roy

AU - Kurzrock, Razelle

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1-5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease.

AB - Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1-5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease.

UR - http://www.scopus.com/inward/record.url?scp=84869206991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869206991&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-12-0358

DO - 10.1158/1535-7163.MCT-12-0358

M3 - Article

VL - 11

SP - 2541

EP - 2546

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -